When compared to existing visualization methods, a new 3D technique with MRI scans doubles the visibility of brain tumors. Since a large number of tumors are discernable, the new process has the potential to make it easier to treat them earlier and at smaller, more manageable stages.

Robert Edelman, M.D., is an inventor, lead author, and clinical professor of radiology. His work was shared in the Science Advances journal. He said, “Our goal is for the new technique – T1RESS – to help thousands of patients by allowing malignant tumors to be detected at an earlier, more curable stage.”

According to the American Brain Tumor Association, 700,000 Americans are living with brain tumors and 16,000 will die this year. The new MRI technique can catch the tiny malignant tumors that often escape notice, potentially saving lives and improving outcomes. 

The hope is that those patients undergoing surgery or radiotherapy will receive better clinical outcomes by making the tumor margins on contrast-enhanced scans more visible.

Edelman and his colleagues studied brain tumors in 54 patients to determine how well T1RESS works. He applied magnetic fields and radio waves used to generate MRI signals differently from existing imaging techniques. The new technique uniquely manipulates brain tissue signals to produce images that offer significantly improved tumor visibility. This application makes T1RESS highly sensitive to the T1 shortening effects of paramagnetic contrast agents, but it also reduces the signal intensity of non-enhancing background issues, both improve tumor visualization.

Experimental results showed that the new technique provided a two-fold improvement over existing MRI methods in regards to the contrast between tumors and normal brain tissue. Edelman compared the visualization to seeing more stars: “There just isn’t enough contrast between the stars and the sunlit sky to make them visible. In the case of brain tumors, T1RESS doubles the contrast between tumors and normal brain, so the tumors are more easily detected. It’s like looking at the stars on a dark night instead of a sunny day,” Edelman said. 

A larger, multi-site trial will need to be performed in order to confirm the findings, but the plan is to apply this technique to both prostate and breast cancers as well. If the benefits are confirmed, widespread use will be as simple as the installation of a specialized software package.

Visit the Science Advances website to read the full journal article. For more information about CT Scanners, Linear Accelerators, and the like, contact Acceletronics today.
 

Acceletronics is an industry leader in delivering the best equipment performance and service reliability from CT Scanners and Linear Accelerators across all major brands and models. Call 610-524-3300 or visit our website: https://www.acceletronics.com.

Written by the digital marketing staff at Creative Programs & Systems: www.cpsmi.com.